Skip to content

April 28, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
M&A / Deals
BioMarin acquires Amicus Therapeutics for $4.8bn

M&A / Deals

BioMarin acquires Amicus Therapeutics for $4.8bn

Pharmaceutical Technology

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.

Read full story

pharminent April 28, 2026 (Last updated: April 28, 2026)

Pharmaceutical Technology

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.

Read full story

Post navigation

Previous: FDA approves AstraZeneca’s Saphnelo for SLE

Next: Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Related Stories

M&A / Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

pharminent April 28, 2026

M&A / Deals

Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

pharminent April 27, 2026

M&A / Deals

Sun Pharma to acquire Organon for $11.75bn

pharminent April 27, 2026

You May Have Missed

Clinical Data

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

pharminent April 28, 2026

Clinical Data

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

pharminent April 28, 2026

M&A / Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

pharminent April 28, 2026

Regulatory

GSK eyes October FDA verdict on chronic hep B drug

pharminent April 28, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.